SCHEMBL10121150

SCHEMBL10121150

C=S1(=O)CCN(C)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL209495 0.73
SCHEMBL12772862 0.71 SMN1; SMN2 (0.36)
Hydrochloric Acid SCHEMBL28503994 0.71 RAB9A (0.38)
SCHEMBL12854185 0.69
SCHEMBL6125031 0.68
SCHEMBL4763102 0.68
SCHEMBL7051483 0.66
SCHEMBL26702 0.66
SCHEMBL6738669 0.65
SCHEMBL8325180 0.65 RAB9A (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9708314-B2 Heterocyclic amide compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-07-18 US disclosed
US-20170143718-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME BIOFOCUS DPI LTD. (GB) 2017-05-25 US disclosed
EP-2701510-B1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME USHER III INITIATIVE INC (US) 2017-02-15 EP disclosed
US-9549910-B2 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome USHER III INITIATIVE, INC. (US) 2017-01-24 US disclosed
US-20160158172-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME USHER III INITIATIVE, INC. 2016-06-09 US disclosed
US-20160108037-A1 HETEROCYCLIC AMIDE COMPOUND NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-04-21 US disclosed
US-20160108016-A1 Novel Cannabinergic Compounds and Uses Thereof NORTHEASTERN UNIVERSITY (US) 2016-04-21 US disclosed
US-9260381-B2 Pyrazolopyridazines and methods for treating retinal degenerative diseases and hearing loss associated with usher syndrome USHER III INITIATIVE, INC. (US) 2016-02-16 US disclosed
US-20150266812-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME USHER III INITIATIVE, INC. 2015-09-24 US disclosed
US-9079909-B2 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome USHER III INITIATIVE, INC. (US) 2015-07-14 US disclosed
US-8236766-B2 Uses of synthetic peptide amides CARA THERAPEUTICS, INC. (US) 2012-08-07 US disclosed
US-8119796-B2 Biphenyl compounds useful as muscarinic receptor antagonists THERAVANCE, INC. (US) 2012-02-21 US disclosed
US-20120022045-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS VENKATRAMAN SHANKAR (US) 2012-01-26 US disclosed
US-20110275621-A1 HIV INTEGRASE INHIBITORS SCHERING CORPORATION 2011-11-10 US disclosed
US-20110251177-A1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2011-10-13 US disclosed
US-20110245296-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK CANADA INC. (CA) 2011-10-06 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed
US-20070276008-A1 Pharmaceutical formulation comprising glycine as a stabilizer EISAI COMPANY LIMITED (JP) 2007-11-29 US disclosed
US-7230014-B1 Pharmaceutical formulation comprising glycine as a stabilizer EISAI CO., LTD. (JP) 2007-06-12 US disclosed
US-20070060622-A1 Compositions and methods using proton pump inhibitors EISAI CO., LTD. (JP) 2007-03-15 US disclosed